Medicine Recommendations

Urinary frequency, urgency, and incontinence

Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)

NICE TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease

Suppression of inflammatory and allergic disorders

treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases

Degarelix for treating advanced hormone-dependent prostate cancer (NICE TA404)

Hyponatraemia

Denosumab for treatment of Glucocorticoid-induced osteoporosis

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of osteoporotic fractures in men

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of osteoporotic fractures in postmenopausal women (NICE TA204)

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE TA265)

NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours 

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

MHRA Drug Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Deucravacitinib for treating moderate to severe plaque psoriasis

NICE TA 907 - Deucravacitinib for treating moderate to severe plaque psoriasis

Bowel obstruction - reduction of tumour oedema associated with bowel obstruction

Breathlessness

Corticosteroids in palliative care - Anorexia, Adjuvant analgesic, Nausea and vomiting associated with chemotherapy, Obstructive syndromes, Raised intracranial pressure, Spinal cord compression

Nausea and vomiting - raised Intracranial Pressure

Palliative care emergencies - SVC obstruction AND Metastatic spinal cord compression

Macular Oedema - retinal vein occlusion (NICE TA229)

Treating non-infectious uveitis (NICE TA460)

Treating diabetic macular oedema - NICE TA824

NICE TA824 - Dexamethasone intravitreal implant for treating diabetic macular oedema

ADHD in children, adolescents and adults

Anxiety

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Seizures

Dibotermin alfa is recommended in Lancashire and South Cumbria for the treatment of acute tibia grade IIIB fractures in adults (as assessed on the Gustilo-Anderson scale), as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation in hospital settings.

Dibotermin alfa is not recommended in Lancashire and South Cumbria for use outside of the licensed indication for the treatment of non-union long bone fractures